Current state of immunotherapy for bladder cancer

Wassim Kassouf; Ashish M. Kamat

doi:10.1586/14737140.4.6.1037

Current state of immunotherapy for bladder cancer

Wassim Kassouf, Ashish M. Kamat

Urology

Research output: Contribution to journal › Review article › peer-review

16 Scopus citations

Abstract

Bacillus Calmette-Guerin (BCG) has been shown to be the most effective agent for the treatment of superficial bladder cancer since its approval by the US Food and Drug Administration for the treatment of carcinoma in situ of the bladder in 1990. Recently, augmentation of BCG immunotherapy with interferon-α_2b and other agents is emerging as salvage therapy for those patients who fail initial treatment. This review summarizes the role of various immunotherapeutic agents in the treatment of bladder cancer, with special emphasis on the appropriate administration and schedule of BCG therapy as well as salvage with the combination of BCG with interferon-α_2b.

Original language	English (US)
Pages (from-to)	1037-1046
Number of pages	10
Journal	Expert review of anticancer therapy
Volume	4
Issue number	6
DOIs	https://doi.org/10.1586/14737140.4.6.1037
State	Published - Dec 2004

Keywords

BCG
Bladder cancer
Immunotherapy
Interferon
Transitional cell carcinoma

ASJC Scopus subject areas

Oncology
Pharmacology (medical)

Access to Document

10.1586/14737140.4.6.1037

Cite this

@article{bbabfc5a24ee45d5b53b1387e16265cf,

title = "Current state of immunotherapy for bladder cancer",

abstract = "Bacillus Calmette-Guerin (BCG) has been shown to be the most effective agent for the treatment of superficial bladder cancer since its approval by the US Food and Drug Administration for the treatment of carcinoma in situ of the bladder in 1990. Recently, augmentation of BCG immunotherapy with interferon-α2b and other agents is emerging as salvage therapy for those patients who fail initial treatment. This review summarizes the role of various immunotherapeutic agents in the treatment of bladder cancer, with special emphasis on the appropriate administration and schedule of BCG therapy as well as salvage with the combination of BCG with interferon-α2b.",

keywords = "BCG, Bladder cancer, Immunotherapy, Interferon, Transitional cell carcinoma",

author = "Wassim Kassouf and Kamat, {Ashish M.}",

year = "2004",

month = dec,

doi = "10.1586/14737140.4.6.1037",

language = "English (US)",

volume = "4",

pages = "1037--1046",

journal = "Expert review of anticancer therapy",

issn = "1473-7140",

publisher = "Expert Reviews Ltd.",

number = "6",

}

TY - JOUR

T1 - Current state of immunotherapy for bladder cancer

AU - Kassouf, Wassim

AU - Kamat, Ashish M.

PY - 2004/12

Y1 - 2004/12

N2 - Bacillus Calmette-Guerin (BCG) has been shown to be the most effective agent for the treatment of superficial bladder cancer since its approval by the US Food and Drug Administration for the treatment of carcinoma in situ of the bladder in 1990. Recently, augmentation of BCG immunotherapy with interferon-α2b and other agents is emerging as salvage therapy for those patients who fail initial treatment. This review summarizes the role of various immunotherapeutic agents in the treatment of bladder cancer, with special emphasis on the appropriate administration and schedule of BCG therapy as well as salvage with the combination of BCG with interferon-α2b.

AB - Bacillus Calmette-Guerin (BCG) has been shown to be the most effective agent for the treatment of superficial bladder cancer since its approval by the US Food and Drug Administration for the treatment of carcinoma in situ of the bladder in 1990. Recently, augmentation of BCG immunotherapy with interferon-α2b and other agents is emerging as salvage therapy for those patients who fail initial treatment. This review summarizes the role of various immunotherapeutic agents in the treatment of bladder cancer, with special emphasis on the appropriate administration and schedule of BCG therapy as well as salvage with the combination of BCG with interferon-α2b.

KW - BCG

KW - Bladder cancer

KW - Immunotherapy

KW - Interferon

KW - Transitional cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=10644275289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10644275289&partnerID=8YFLogxK

U2 - 10.1586/14737140.4.6.1037

DO - 10.1586/14737140.4.6.1037

M3 - Review article

C2 - 15606331

AN - SCOPUS:10644275289

SN - 1473-7140

VL - 4

SP - 1037

EP - 1046

JO - Expert review of anticancer therapy

JF - Expert review of anticancer therapy

IS - 6

ER -

Current state of immunotherapy for bladder cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this